Why is Regeneron Pharmaceuticals stock plunging today?

Regeneron fell 10.5% pre-open to $625 after its Phase 3 fianlimab/cemiplimab melanoma trial missed the primary endpoint, eliminating a near-term regulatory path in that indication. Citi downgraded REGN from Buy to Neutral and cut its price target to $700 from $900, while the stock traded well below the prior close of $698.25. The miss also weakens the drug's longer-term pipeline profile, even as Dupixent, Eylea HD, and the Opdualag head-to-head trial remain intact.

Analysis

This is less a one-day earnings-style gap and more a valuation reset on REGN’s optionality. The market had been paying for a credible second growth leg in immuno-oncology; removing that path forces the stock back to a simpler lens where the core franchise quality matters, but the multiple should compress because pipeline scarcity becomes more visible. In a tape this weak, that kind of multiple de-rating often persists for several sessions even if the absolute business impact is limited, because fast-money holders de-risk first and reassess later.

The second-order beneficiary is not a single named competitor so much as the broader class of checkpoint-adjacent assets with cleaner clinical visibility. The failure makes it harder for investors to justify buying late-stage combo platforms without clear differentiation versus established PD-1 backbones, which should widen the spread between “platform story” biotech and companies with already-monetizing assets. It also reduces near-term appetite for speculative LAG-3 readthrough trades, where capital is likely to rotate toward assets with better prior probabilities and shorter time-to-catalyst.

The key risk is that the current move overshoots the cash-flow reality: Dupixent and Eylea HD still anchor the equity story, so a full structural break is unlikely unless additional pipeline disappointments follow. That creates a months-long setup where the stock may be range-bound below prior highs but not necessarily trend lower in a straight line. The cleanest rebound trigger would be either a broader biotech factor turn or credible evidence that the remaining oncology program can still support meaningful commercial value, but that is a longer-dated catalyst, not a days-to-weeks rescue.

Consensus is probably underestimating how much this changes investor behavior rather than near-term earnings. The real damage is to sentiment and valuation discipline: after one headline miss, the market will demand a higher bar for any future pipeline claim, which can cap multiple expansion even if fundamentals hold. That said, if the stock continues to trade like a broken story despite core franchise durability, the selloff may become attractive for fundamental longs once the forced selling clears.

Key Decisions for Investors

• Short REGN into the next 1-3 trading sessions only if the stock fails to reclaim the premarket gap; target a tactical retracement to the prior support zone, with a tight stop above the first post-news bounce high. Risk/reward favors momentum continuation while analyst downgrades and de-risking flows are still working.
• Sell downside put spreads on REGN in 1-2 month tenors rather than outright puts if you want to express bearishness with defined risk; the core franchise should limit crash risk, so premium harvesting is preferable to naked downside exposure.
• Pair trade: long a higher-visibility large-cap biotech/franchise name versus short REGN over the next 4-8 weeks. The idea is to isolate pipeline optionality de-rating from broader sector beta and capture relative multiple compression.
• Avoid initiating fresh long exposure for 2-3 weeks; wait for post-event analyst revisions and estimate resets to settle. If REGN stabilizes while the market remains risk-off, that would improve risk/reward for a medium-term re-entry.